Introduction: Various definitions of very severe (VS) tricuspid regurgitation (TR) have been proposed based on the effective regurgitant orifice area (EROA) or tricuspid coaptation gap (TCG). Because of the inherent limitations associated with the EROA, we hypothesized that the TCG would be more suitable for defining VSTR and predicting outcomes.

Materials And Methods: In this French multicentre retrospective study, we included 606 patients with ≥moderate-to-severe isolated functional TR (without structural valve disease or an overt cardiac cause) according to the recommendations of the European Association of Cardiovascular Imaging. Patients were further stratified into VSTR according to the EROA (≥60 mm) and then according to the TCG (≥10 mm). The primary endpoint was all-cause mortality and the secondary endpoint was cardiovascular mortality.

Results: The relationship between the EROA and TCG was poor (=0.22), especially when the size of the defect was large. Four-year survival was comparable between patients with an EROA <60 mm vs. ≥60 mm (68 ± 3% vs. 64 ± 5%,  = 0.89). A TCG ≥10 mm was associated with lower four-year survival than a TCG <10 mm (53 ± 7% vs. 69 ± 3%,  < 0.001). After adjustment for covariates, including comorbidity, symptoms, dose of diuretics, and right ventricular dilatation and dysfunction, a TCG ≥10 mm remained independently associated with higher all-cause mortality (adjusted HR[95% CI] = 1.47[1.13-2.21],  = 0.019) and cardiovascular mortality (adjusted HR[95% CI] = 2.12[1.33-3.25],  = 0.001), whereas an EROA ≥60 mm was not associated with all-cause or cardiovascular mortality (adjusted HR[95% CI]: 1.16[0.81-1.64],  = 0.416, and adjusted HR[95% CI]: 1.07[0.68-1.68],  = 0.784, respectively).

Conclusion: The correlation between the TCG and EROA is weak and decreases with increasing defect size. A TCG ≥10 mm is associated with increased all-cause and cardiovascular mortality and should be used to define VSTR in isolated significant functional TR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172668PMC
http://dx.doi.org/10.3389/fcvm.2023.1090572DOI Listing

Publication Analysis

Top Keywords

effective regurgitant
8
regurgitant orifice
8
orifice area
8
tricuspid coaptation
8
coaptation gap
8
severe tricuspid
8
tricuspid regurgitation
8
eroa
5
comparison effective
4
area pisa
4

Similar Publications

Eosinophilic oesophagitis (EoE) is a chronic and progressive immune-mediated condition, typically affecting young atopic male adults and potentially leads to organ dysfunction and fibrosis. The clinical spectrum widely varies -from non-troublesome dysphagia to food impaction- and hence the rate of misdiagnosis and diagnostic delay are high, especially when presenting with minor symptoms, such as heartburn and acid regurgitation. There have been several major therapeutic breakthroughs for the management of EoE in recent years.

View Article and Find Full Text PDF

Noncardiogenic pulmonary edema after cardiac surgery is a rare but severe complication. The etiology remains poorly understood; however, the issue may arise from multiple sources. Possible causes include a significant inflammatory response or an autoimmune process.

View Article and Find Full Text PDF

Comparison of Alcohol Septal Ablation with Mavacamten in Obstructive Hypertrophic Cardiomyopathy.

Am J Cardiol

December 2024

Northwestern University, Feinberg School of Medicine, Chicago IL 60611; The Hypertrophic Cardiomyopathy Program at the Bluhm Cardiovascular Institute, Chicago IL 60611; Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago IL 60611.

Background: Obstructive hypertrophic cardiomyopathy (HCM) is associated with significant morbidity due to left ventricular outflow tract (LVOT) obstruction. While alcohol septal ablation (ASA) is an established interventional treatment, mavacamten, a novel cardiac myosin inhibitor, has emerged as a non-invasive pharmacological alternative. Understanding the comparative efficacy of these two treatments is important for optimizing patient care.

View Article and Find Full Text PDF

Functional mitral regurgitation (MR) is associated with increased cardiovascular morbidity and mortality and over the past decade, the diagnosis of atrial functional mitral regurgitation (aFMR) has been increasingly observed in the elderly, especially in those with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Annular enlargement, perturbations of annular contraction, and atriogenic leaflet tethering distinguish the pathophysiology of aFMR from the one of ventricular origin. However, no consensus provides recommendations regarding the differential diagnosis and the subsequent management of aFMR.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiac resynchronization therapy (CRT) improves functional mitral regurgitation (FMR) by coordinating heart muscle segments, especially between papillary muscles, beyond just boosting left ventricular (LV) performance.
  • Eighteen patients with dilated cardiomyopathy underwent tests to measure heart function, and biventricular pacing showed a significant reduction in mitral regurgitation despite some patients showing no change in LV pressure.
  • The study concludes that CRT effectively lowers FMR independently of LV systolic function improvements, highlighting the importance of understanding its mechanisms for better treatment outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!